{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T07:34:25Z","timestamp":1747208065309,"version":"3.40.5"},"reference-count":136,"publisher":"Informa UK Limited","issue":"15","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Microbiol."],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.2217\/fmb-2020-0174","type":"journal-article","created":{"date-parts":[[2020,11,3]],"date-time":"2020-11-03T11:01:23Z","timestamp":1604401283000},"page":"1507-1521","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":2,"title":["Coronavirus Pandemic: Treatment and Future Prevention"],"prefix":"10.1080","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0580-5209","authenticated-orcid":false,"given":"Kenneth","family":"Lundstrom","sequence":"first","affiliation":[{"name":"PanTherapeutics,\rRte de Lavaux 49,\r1095\rLutry,\rSwitzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2020,11,3]]},"reference":[{"key":"e_1_3_2_3_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.3.5568.767"},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.3181\/00379727-121-30734"},{"key":"e_1_3_2_5_1","doi-asserted-by":"publisher","DOI":"10.1098\/rstb.2004.1490"},{"key":"e_1_3_2_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.prrv.2004.07.009"},{"key":"e_1_3_2_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra032498"},{"key":"e_1_3_2_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1211721"},{"key":"e_1_3_2_9_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-016-2137-3"},{"key":"e_1_3_2_10_1","doi-asserted-by":"publisher","DOI":"10.3201\/eid2004.131746"},{"key":"e_1_3_2_11_1","doi-asserted-by":"publisher","DOI":"10.3201\/eid2002.131182"},{"key":"e_1_3_2_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1401505"},{"key":"e_1_3_2_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10729-020-09504-6"},{"key":"e_1_3_2_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2020.102434"},{"key":"e_1_3_2_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmii.2020.02.012"},{"key":"e_1_3_2_16_1","unstructured":"Worldometer . COVID-19 coronavirus pandemic. (2020). http:\/\/www.worldometers.info\/coronavirus\/"},{"key":"e_1_3_2_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/joim.13091"},{"key":"e_1_3_2_18_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.inf.0000188166.17324.60"},{"key":"e_1_3_2_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2012.04.011"},{"key":"e_1_3_2_20_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00676-14"},{"key":"e_1_3_2_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature02145"},{"key":"e_1_3_2_22_1","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines8050109"},{"key":"e_1_3_2_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2020.117592"},{"key":"e_1_3_2_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2019.03.010"},{"key":"e_1_3_2_25_1","doi-asserted-by":"publisher","DOI":"10.2147\/tcrm.s3285"},{"key":"e_1_3_2_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature17180"},{"key":"e_1_3_2_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-010-8243-x"},{"key":"e_1_3_2_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2286-9"},{"key":"e_1_3_2_29_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiv392"},{"key":"e_1_3_2_30_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-019-3846-x"},{"key":"e_1_3_2_31_1","doi-asserted-by":"publisher","DOI":"10.1136\/thorax.2003.012658"},{"key":"e_1_3_2_32_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2001282"},{"key":"e_1_3_2_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.medj.2020.04.001"},{"key":"e_1_3_2_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eng.2020.03.007"},{"key":"e_1_3_2_35_1","unstructured":"Clinical Trials Arena . Glenmark begins Phase III trials of favipiravir for COVID-19 in India. http:\/\/www.clinicaltrialsarena.com\/news\/glenmark-favipiravir-trial-begins\/"},{"key":"e_1_3_2_36_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2007016"},{"key":"e_1_3_2_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31022-9"},{"key":"e_1_3_2_38_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2007764"},{"key":"e_1_3_2_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.105949"},{"key":"e_1_3_2_40_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m1849"},{"key":"e_1_3_2_41_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-019-3606-y"},{"key":"e_1_3_2_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2015.01.011"},{"key":"e_1_3_2_43_1","first-page":"21","article-title":"Acute eosinophilic pneumonia caused by camostat mesilate: the first case report","volume":"19","author":"Ota S","year":"2016","unstructured":"Ota S , HaraY, KanohSet al. Acute eosinophilic pneumonia caused by camostat mesilate: the first case report. Respir. Med. Case Rep.19, 21\u201323 (2016).","journal-title":"Respir. Med. Case Rep."},{"issue":"20","key":"e_1_3_2_44_1","first-page":"30551","article-title":"Sofosbuvir as repurposed antiviral drug against COVID-19: why were we convinced to evaluate the drug in a registered\/approved clinicsal trial?","volume":"0188","author":"Sayad B","year":"2020","unstructured":"Sayad B , SobhaniM, KhodarahmiR. Sofosbuvir as repurposed antiviral drug against COVID-19: why were we convinced to evaluate the drug in a registered\/approved clinicsal trial?Arch. Med. Res.S0188\u20134409(20), 30551\u201330558 (2020).","journal-title":"Arch. Med. Res."},{"key":"e_1_3_2_45_1","doi-asserted-by":"publisher","DOI":"10.1038\/srep05452"},{"key":"e_1_3_2_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2006.04.014"},{"key":"e_1_3_2_47_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.13535"},{"key":"e_1_3_2_48_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.abb3405"},{"key":"e_1_3_2_49_1","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.22211.2"},{"key":"e_1_3_2_50_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.C300520200"},{"key":"e_1_3_2_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.02.058"},{"key":"e_1_3_2_52_1","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2020.1729069"},{"key":"e_1_3_2_53_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200565180-00012"},{"key":"e_1_3_2_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(17)30109-1"},{"key":"e_1_3_2_55_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-020-00966-9"},{"key":"e_1_3_2_56_1","doi-asserted-by":"publisher","DOI":"10.2183\/pjab.93.027"},{"key":"e_1_3_2_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.106028"},{"key":"e_1_3_2_58_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.8857"},{"key":"e_1_3_2_59_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0888-2"},{"key":"e_1_3_2_60_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11739-020-02345-9"},{"key":"e_1_3_2_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.02.052"},{"key":"e_1_3_2_62_1","unstructured":"Camostat mesylate in COVID-19 outpatients. NCT04353284 (2020). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04353284"},{"key":"e_1_3_2_63_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13027-020-00302-x"},{"key":"e_1_3_2_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2020.104859"},{"key":"e_1_3_2_65_1","doi-asserted-by":"publisher","DOI":"10.3390\/v11070625"},{"key":"e_1_3_2_66_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-017-2253-8"},{"key":"e_1_3_2_67_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2223-y"},{"key":"e_1_3_2_68_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0081587"},{"key":"e_1_3_2_69_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13238-017-0473-8"},{"key":"e_1_3_2_70_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature02145"},{"key":"e_1_3_2_71_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1301336110"},{"key":"e_1_3_2_72_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-08273-7"},{"key":"e_1_3_2_73_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-16256-y"},{"key":"e_1_3_2_74_1","doi-asserted-by":"publisher","DOI":"10.1002\/ddr.21656"},{"key":"e_1_3_2_75_1","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(93)90529-Y"},{"key":"e_1_3_2_76_1","doi-asserted-by":"publisher","DOI":"10.2174\/157016311795563857"},{"key":"e_1_3_2_77_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-9525(02)00005-7"},{"key":"e_1_3_2_78_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-5793(04)00087-0"},{"key":"e_1_3_2_79_1","doi-asserted-by":"publisher","DOI":"10.1177\/135965350400900310"},{"key":"e_1_3_2_80_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.gt.3302682"},{"key":"e_1_3_2_81_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4939-2438-7_19"},{"key":"e_1_3_2_82_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-008-0495-5"},{"key":"e_1_3_2_83_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12539-015-0266-9"},{"key":"e_1_3_2_84_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11262-019-01701-y"},{"key":"e_1_3_2_85_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12250-020-00221-6"},{"issue":"2","key":"e_1_3_2_86_1","first-page":"212","article-title":"The 2019 novel coronavirus resource","volume":"42","author":"Zhao WM","year":"2020","unstructured":"Zhao WM , SongSH, ChenMLet al. The 2019 novel coronavirus resource. Yi Chuan42(2), 212\u2013222 (2020).","journal-title":"Yi Chuan"},{"key":"e_1_3_2_87_1","unstructured":"WHO . DRAFT landscape of COVID-19 candidate vaccines. (2020). http:\/\/www.who.int\/blueprint\/priority-diseases\/key-action\/novel-coronavirus-landscape-ncov.pdf"},{"key":"e_1_3_2_88_1","doi-asserted-by":"publisher","DOI":"10.1038\/d41573-020-00073-5"},{"key":"e_1_3_2_89_1","unstructured":"Codagenix and serum institute of india initiate co-development of a scalable live-attenuated vaccine against the 2019 novel coronavirus COVID-19. La Merie Publishing (2020). https:\/\/pipelinereview.com"},{"key":"e_1_3_2_90_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.06.008"},{"key":"e_1_3_2_91_1","unstructured":"The University of Queensland CEPI and CSL partner to advance development and manufacture of COVID-19 vaccine candidate. https:\/\/www.csl.com (2020)."},{"key":"e_1_3_2_92_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40475-020-00201-6"},{"key":"e_1_3_2_93_1","unstructured":"Sanofi and GSK to join forces in unprecedented vaccine collaboration to fight COVID-19. https:\/\/ww.sanofi.com (2020)."},{"key":"e_1_3_2_94_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2608-y"},{"key":"e_1_3_2_95_1","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.00554-20"},{"key":"e_1_3_2_96_1","doi-asserted-by":"publisher","DOI":"10.12659\/MSM.926016"},{"key":"e_1_3_2_97_1","unstructured":"COVID-19 vaccine development: an interview with GeoVax (2020). http:\/\/www.technologynetworks.com"},{"key":"e_1_3_2_98_1","unstructured":"Themis collaborates with ABL Europe to manufacture its SARS-CoV-2 vaccine candidate in France (2020). http:\/\/www.themisbio.com"},{"key":"e_1_3_2_99_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-16505-0"},{"key":"e_1_3_2_100_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.abc6284"},{"key":"e_1_3_2_101_1","unstructured":"About CureVac's activities regarding an mRNA-based vaccine against COVID-19 (2020). http:\/\/www.curevac.com\/covid-19"},{"key":"e_1_3_2_102_1","unstructured":"RNA manufacturing platform (2020). http:\/\/www.imperial.ac.uk\/future-vaccine-hub\/workstreams\/rna-vaccine-manufacture\/"},{"key":"e_1_3_2_103_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M114.620534"},{"key":"e_1_3_2_104_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.dib.2018.10.030"},{"key":"e_1_3_2_105_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2006.01.059"},{"key":"e_1_3_2_106_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-19041-y"},{"key":"e_1_3_2_107_1","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens8030133"},{"key":"e_1_3_2_108_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2013.05.086"},{"key":"e_1_3_2_109_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32488-7"},{"key":"e_1_3_2_110_1","doi-asserted-by":"publisher","DOI":"10.3390\/molecules23123310"},{"key":"e_1_3_2_111_1","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.aaw6647"},{"key":"e_1_3_2_112_1","doi-asserted-by":"publisher","DOI":"10.2174\/1566523213666131125095046"},{"key":"e_1_3_2_113_1","unstructured":"A randomized double-blind placebo parallel-controlled Phase I\/II clinical trial for inactivated Novel Coronavirus Pneumonia vaccine (Vero cells). ChiCTR2000031809. http:\/\/www.chictr.org.cn\/showprojen.aspx?proj=52227"},{"key":"e_1_3_2_114_1","unstructured":"A Phase I\/II clinical trial for inactivated novel coronavirus (2019-CoV) vaccine (Vero cells). ChiCTR2000032459. http:\/\/www.chictr.org.cn\/showproj.aspx?proj=53003"},{"key":"e_1_3_2_115_1","unstructured":"China steps up inactivated COVID-19 vaccine development. http:\/\/www.xinhuanet.com\/english\/2020-06\/01\/c_139105909.htm (2020)."},{"key":"e_1_3_2_116_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.abc1932"},{"key":"e_1_3_2_117_1","unstructured":"Safety and immunogenicity study of inactivated vaccine for prevention of SARS-CoV-2 infection (COVID-19). NCT04383574. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04383574"},{"key":"e_1_3_2_118_1","unstructured":"Safety and immunogenicity study of inactivated vaccine for prophylaxis of SARS CoV-2 infection (COVID-19). NCT04352608. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04352608?term=Sinovac&cntry=CN&draw=2"},{"key":"e_1_3_2_119_1","unstructured":"The updated list of COVID-19 vaccines (2020). https:\/\/covidvax.org"},{"key":"e_1_3_2_120_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2016.02.033"},{"key":"e_1_3_2_121_1","unstructured":"Novavax initiates Phase I\/II clinical trial of COVID-19 vaccine (2020). https:\/\/ir.novavax.com"},{"key":"e_1_3_2_122_1","unstructured":"Evaluation of the safety and immunogenicity of a SARS-CoV-2 rS (COVID-19) nanoparticle vaccine with\/without matrix-M adjuvant. NCT04368988. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04368988?term=vaccine&recrs=a&cond=covid-19&draw=2"},{"key":"e_1_3_2_123_1","unstructured":"A Phase I\/II study to determine efficacy safety and immunogenicity of the candidate coronavirus disease (COVID-19) vaccine ChAdOx1 nCoV-19 in UK healthy adult volunteers. 2020-001072-15. http:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-001072-15\/GB"},{"key":"e_1_3_2_124_1","unstructured":"Recruitment to this Phase I\/II study (COV001) is now complete. Recruitment to the Phase II\/III study is ongoing (2020). https:\/\/covid19vaccinetrial.co.uk\/ongoing-studies"},{"key":"e_1_3_2_125_1","unstructured":"A Phase II\/III study to determine the efficacy safety and immunogenicity of the candidate coronavirus disease (COVID-19) vaccine ChAdOx1 nCoV-19. 2020-001228-32. http:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-001228-32\/GB"},{"key":"e_1_3_2_126_1","unstructured":"A Phase I clinical trial for recombinant novel coronavirus (2019-COV) vaccine (adenoviral vector) ChiCTR2000030906. http:\/\/www.chictr.org.cn\/showprojen.aspx?proj=51154"},{"key":"e_1_3_2_127_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31605-6"},{"key":"e_1_3_2_128_1","unstructured":"A randomized double-blinded placebo-controlled Phase II clinical trial for Recombinant Novel Coronavirus (2019-nCOV) Vaccine (Adenovirus Vector) in healthy adults aged above 18 years. ChiCTR2000031781. http:\/\/www.chictr.org.cn\/showprojen.aspx?proj=52006"},{"key":"e_1_3_2_129_1","unstructured":"China's Shenzhen Geno-Immune Medical Institute pursues a COVID-19 vaccine (2020). http:\/\/www.trialsitenews.com\/category\/shenzhen-geno-immune-medical-institute\/"},{"key":"e_1_3_2_130_1","unstructured":"Inovio urgently focused on developing COVID-19 vaccine (2020). http:\/\/www.inovio.com\/our-focus-serving-patients\/covid-19\/"},{"key":"e_1_3_2_131_1","unstructured":"Moderna advances late-stage development of its vaccine (mRNA-1273) against COVID-19 (2020). https:\/\/investors.modernatx.com\/news-releases\/news-release-details\/moderna-advances-late-stage-development-its-vaccine-mrna-1273"},{"key":"e_1_3_2_132_1","unstructured":"Safety and immunogenicity study of 2019-nCoV Vaccine (mRNA-1273) for prophylaxis of SARS-CoV-2 infection (COVID-19). NCT04283461. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04283461?term=vaccine&cond=covid-19&draw=2"},{"key":"e_1_3_2_133_1","unstructured":"Moderna's latest vaccine results are promising \u2013 but it's still too early (2020). http:\/\/www.technologyreview.com\/2020\/05\/18\/1001834\/moderna-coronavirus-vaccine-phase-i-interim-clinical-trial-results\/"},{"key":"e_1_3_2_134_1","unstructured":"Study to describe the safety tolerability immunogenicity and efficacy of rna vaccine candidates against COVID-19 in healthy adults. NCT04368728. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04368728?term=vaccine&cond=covid-19&draw=3"},{"key":"e_1_3_2_135_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2019.03.008"},{"key":"e_1_3_2_136_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI138745"},{"key":"e_1_3_2_137_1","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.25961"},{"key":"e_1_3_2_138_1","doi-asserted-by":"publisher","DOI":"10.18632\/aging.103102"}],"container-title":["Future Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fmb-2020-0174","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T06:40:01Z","timestamp":1719124801000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fmb-2020-0174"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":136,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["10.2217\/fmb-2020-0174"],"URL":"https:\/\/doi.org\/10.2217\/fmb-2020-0174","relation":{},"ISSN":["1746-0913","1746-0921"],"issn-type":[{"type":"print","value":"1746-0913"},{"type":"electronic","value":"1746-0921"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifmb20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifmb20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2020-07-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-10-05","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-11-03","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}